Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
140 hedge funds and large institutions have $941M invested in Day One Biopharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 60 increasing their positions, 23 reducing their positions, and 25 closing their positions.
161% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 23
56% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 25
33% more call options, than puts
Call options by funds: $1.74M | Put options by funds: $1.31M
23.94% more ownership
Funds ownership: 83.18% → 107.12% (+24%)
15% more capital invested
Capital invested by funds: $818M → $941M (+$123M)
11% more funds holding
Funds holding: 126 → 140 (+14)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$22.2M |
| 2 |
BlackRock
New York
|
+$17.1M |
| 3 |
DM
Deerfield Management
New York
|
+$16.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.2M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$5.38M |
| 3 |
Renaissance Technologies
New York
|
-$3.13M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.76M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.36M |
DAWN Hedge Fund Activity: Q2 2023 in Review
140 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q2 2023, worth a combined $941M — up 15% from $818M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new DAWN positions and 25 closed out — a net gain of 14 holders — while 60 added to existing stakes and 23 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $22.2M. The largest seller was Fidelity Investments, cutting an estimated $13.2M.
- 140 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q2 2023, up from 126 in Q1 2023.
- Funds reported $941M of Day One Biopharmaceuticals stock for Q2 2023, up 15% quarter-over-quarter.
- 39 funds opened new Day One Biopharmaceuticals positions in Q2 2023 and 25 closed out, a net change of +14 holders.
- The largest Day One Biopharmaceuticals buyer in Q2 2023 was Adage Capital Partners, an estimated $22.2M added.
- The largest Day One Biopharmaceuticals seller in Q2 2023 was Fidelity Investments, an estimated $13.2M sold.
Based on aggregated 13F filings for Q2 2023.